



ASGO Webinar Series #40

Antibody-drug conjugates (ADC) in gynecologic oncology

CAROLYN R. ZALAMEDA-CASTRO, MD, MSc

Gynecologic Oncologist

University of the Philippines – Philippine General Hospital

Discussant



What are your thoughts on...

1. ADCs being ***THERANOSTIC***?
2. Is there a need to test for the overexpression of surface/target antigens on the cancer cells before ADCs are recommended?
3. ADCs as **FIRST-LINE** treatment of gynecologic cancer?

Congratulations and Thank you! 😊